Trial comparing treatments for Non-Small Cell Lung Cancer
Official title Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
ClinicalTrials.gov ID: NCT07100080
What this study is testing
What is Iza-bren?
This is an investigational medicine being studied as a potential treatment for non-small cell lung cancer. It is designed to attach to a specific protein on cancer cells and deliver a chemotherapy drug directly to them.
Also referred to as Izalontamab brengitecan.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study compares a new drug, Izalontamab Brengitecan, with standard platinum‑pemetrexed treatment to see which works better after EGFR‑targeted therapy fails.
- Who it's for
- Adults with EGFR‑mutated non‑small cell lung cancer who have already tried EGFR‑targeted drugs.
- What's involved
- Participants will receive either Izalontamab Brengitecan or platinum‑pemetrexed, with regular clinic visits and medical tests to monitor safety and effectiveness.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Non-squamous NSCLC, not amenable to treatment in curative intent.
- Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation).
- Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as...
- Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin) in combination with pemetrexed with or without...
You likely can't join if
- Inadequate organ function and/or bone marrow reserve.
- Leptomeningeal metastases or spinal cord compression.
- Poorly controlled systemic medical conditions.
- Other protocol-defined inclusion/exclusion criteria apply.
The study team makes the final eligibility decision.
Where it is enrolling
- Irvine, California, United States
- Orange, California, United States
- Edwards, Colorado, United States
- Atlanta, Georgia, United States
- Columbus, Georgia, United States
- Chicago, Illinois, United States
- Boston, Massachusetts, United States
- St Louis, Missouri, United States
- Reno, Nevada, United States
- Mineola, New York, United States
- New York, New York, United States
- Rochester, New York, United States
- Cleveland, Ohio, United States
- Columbus, Ohio, United States
- Portland, Oregon, United States
- Philadelphia, Pennsylvania, United States
- Pittsburgh, Pennsylvania, United States
- Nashville, Tennessee, United States
- Houston, Texas, United States
- Charlottesville, Virginia, United States
+ 18 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Irvine, California, United States; Orange, California, United States; Edwards, Colorado, United States; Atlanta, Georgia, United States; Columbus, Georgia, United States; Chicago, Illinois, United States and 32 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.